LungLife AI, Inc.

Headquartered in Thousand Oaks, California, and established in 2009, LungLife AI, Inc. is a diagnostics firm dedicated to creating AI-powered clinical solutions for lung cancer. The company, which was known as Cynvenio Biosystems, Inc. until its renaming in May 2019, operates in both the United States and China. Its primary focus involves the ongoing development of LungLB, a blood test engineered to differentiate between cancerous and non-cancerous lung nodules initially discovered through CT scans.